TARDBP and synucleinopathy: Still, they differ in their ultimate manifestation (e.g., dementia, Parkinsonism, motor neuron impairment), the affected brain region [e.g., hippocampus (AD), Substantia nigra (PD), striatum (HD), upper and lower motor neurons (ALS)], and the kind of proteinopathy [amyloidosis, tauopathies (AD)], a-synucleinopathy (PD), CAG triplet elongation (HD) and TAR DNA-binding protein 43 (TDP-43) aggregates (ALS) (Roos, 2010; Zarei et al., 2015; Rosenberg et al., 2016; Armstrong and Okun, 2020; Pathak et al., 2021).